Neurocrine Biosciences, Inc. reaffirmed sales guidance for the full year of 2024. For the year, company expects INGREZZA Net Product Sales of $2,100 million to $2,200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -0.91% | -2.86% | +2.77% |
May. 31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.77% | 13.63B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024